Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy.<br /><br />The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and enhance the effects of current standard-of-care therapies. Engineered for systemic delivery, Theriva’s oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment (intratumoral, intravitreal).
